Cannovum Cannabis AG (27N0.DE) Stock
Cannovum Cannabis AG

Company profile
Cannovum Cannabis reported no revenue for fiscal year 2024.
What stands out
- It reported a net loss in each of its last 5 fiscal years; the loss narrowed from 3.17 million EUR in fiscal year 2023 to 401,396 EUR in fiscal year 2024.
Figures from company filings; latest fiscal year ended December 31, 2024.
About Cannovum Cannabis AG
Cannovum Cannabis AG engages in the manufacturing, wholesaling, and importing of medical cannabis products in Berlin. It also focuses on the import of medical cannabis and medical-scientific education, as well as distribution for facilitated access to cannabis-based therapies. The company was formerly known as Cannovum AG and changed its name to Cannovum Cannabis AG in April 2023. Cannovum Cannabis AG was incorporated in 2018 and is based in Berlin, Germany.
Leadership
- Pia Marten — Co-Founder, CEO & Member of Management Board
- Marius Koose — Co-Founder
- Paul Weber — Head of Sales
- Timo Kinder — Head of Quality Assurance
- Klaus Madzia — C.M.O.
What companies are similar to Cannovum Cannabis?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Bayer Aktiengesellschaft (BAYN.DE), Dermapharm Holding SE (DMP.DE), Biotest Aktiengesellschaft (BIO3.DE).
Has Cannovum Cannabis made a profit in recent years?
Net income by fiscal year: FY2020, a loss of 30,574 EUR; FY2021, a loss of 107,988 EUR; FY2022, a loss of 9.92 million EUR; FY2023, a loss of 3.17 million EUR; FY2024, a loss of 401,396 EUR. It reported a net loss in each of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Cannovum Cannabis AG (27N0.DE)”, data as of Dec 31, 2024, https://dataporium.tech/stocks/27N0.DE